Literature DB >> 1431250

Characterization of the serum antibody response to the capsular polysaccharide of Haemophilus influenzae type b in children with invasive infections.

B Trollfors1, T Lagergård, B A Claesson, E Thornberg, J Martinell, R Schneerson.   

Abstract

The serum antibody response to the capsular polysaccharide of Haemophilus influenzae type b (Hib) was studied in 30 children aged 1 day-5 years with invasive Hib infections. From each child, serum was obtained 0-2 days, 5-11 days, 1 month, and 6-12 months after onset of symptoms. Total antibodies were determined with RIA and isotypes with ELISA. Only 2 children had antibody levels above the estimated protective level (0.15 microgram/mL) in the first serum sample. The antibody response was age dependent with wide individual variations. Children > or = 2 years had increases in IgG, IgM, and IgA antibodies with predominance of IgG. The initial IgG response was IgG1 and IgG2 with predominance of IgG1. In the last serum sample, IgG1 antibodies had decreased while IgG2 antibodies remained unchanged. Only 2 of 7 children < 1 year had a detectable antibody response. The correlation coefficient for total antibodies compared with the sum of IgG, IgM, and IgA was .88 (P < .0001) and for IgG compared with the sum of IgG1 and IgG2 was .97 (P < .0001).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1431250     DOI: 10.1093/infdis/166.6.1335

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.

Authors:  Nadine G Rouphael; Sarah Satola; Monica M Farley; Karen Rudolph; Daniel S Schmidt; Patricia Gomez-de-León; John B Robbins; Rachel Schneerson; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

2.  Characterization of the impaired antipneumococcal polysacharide antibody production in immunosuppressed pediatric patients following cardiac transplantation.

Authors:  A R Gennery; A J Cant; C I Baldwin; J E Calvert
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

3.  Differing antibody responses to Haemophilus influenzae type b after meningitis or epiglottitis.

Authors:  P D Johnson; M Hanlon; D Isaacs; G L Gilbert
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

4.  Neisserial immunoglobulin A1 protease induces specific T-cell responses in humans.

Authors:  Anastasios Tsirpouchtsidis; Robert Hurwitz; Volker Brinkmann; Thomas F Meyer; Gaby Haas
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  A Cation-Binding Surface Protein as a Vaccine Antigen To Prevent Moraxella catarrhalis Otitis Media and Infections in Chronic Obstructive Pulmonary Disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Antoinette Johnson; Gregory E Wilding; Mary Koszelak-Rosenblum; Michael G Malkowski
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

Review 6.  Haemophilus influenzae type b conjugate vaccines.

Authors:  Dominic F Kelly; E Richard Moxon; Andrew J Pollard
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

7.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

8.  Antibody response to polyribosyl-ribitol phosphate antigen of Haemophilus influenzae in Ecuadorian and German children.

Authors:  H Brüssow; J Sidoti; A Rytz
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

9.  Humoral immune responses to Neisseria meningitidis in children.

Authors:  A J Pollard; R Galassini; E M van der Voort; R Booy; P Langford; S Nadel; C Ison; J S Kroll; J Poolman; M Levin
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.